SpyGlass Pharma, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, the company reported net loss was USD 12.56 million compared to USD 8.4 million a year ago. Basic loss per share from continuing operations was USD 5.72 compared to USD 4.58 a year ago.
For the full year, net loss was USD 39.87 million compared to USD 29.16 million a year ago. Basic loss per share from continuing operations was USD 17.98 compared to USD 16.31 a year ago. Diluted loss per share from continuing operations was USD 17.98 compared to USD 16.31 a year ago.